Rocket Pharmaceuticals, Inc. - Common Stock (RCKT)
3.0100
-0.1000 (-3.22%)
NASDAQ · Last Trade: Jul 30th, 2:58 AM EDT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 29, 2025
NEW YORK - July 29, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 29, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · July 28, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 28, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 28, 2025
NEW YORK - July 28, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 28, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · July 25, 2025
NEW YORK - July 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 25, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 25, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 24, 2025
NEW YORK - July 24, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 24, 2025
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth.
By Rocket Pharmaceuticals, Inc. · Via Business Wire · July 24, 2025
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 23, 2025
NEW YORK - July 23, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 23, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 22, 2025
NEW YORK - July 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 21, 2025
NEW YORK - July 21, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 21, 2025
NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
By Bernstein Liebhard LLP · Via GlobeNewswire · July 21, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · July 20, 2025
NEW YORK, July 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · July 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · July 18, 2025
NEW YORK - July 18, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Via TheNewswire.com · July 18, 2025
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
By Pomerantz LLP · Via GlobeNewswire · July 18, 2025